Diet and metabolic syndrome: An overview

Current Vascular Pharmacology

Volumn 11, Issue 6, 2013, Pages 842-857

  Keane, Deirdre ^a   Kelly, Stacey ^a   Healy, Niamh P ^a   McArdle, Maeve A ^a   Holohan, Kieran ^a   Roche, Helen M ^a  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

Diets; Fatty acids; Functional foods; Glycaemic index; Metabolic syndrome; Nutrition

Indexed keywords

CARBOHYDRATE; FAT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; POLYUNSATURATED FATTY ACID; SATURATED FATTY ACID; TRIACYLGLYCEROL;

ADIPOSE TISSUE; ARTICLE; BLOOD PRESSURE; BODY WEIGHT; CARDIOVASCULAR DISEASE; DIABETES MELLITUS; DIET THERAPY; EXERCISE; FUNCTIONAL FOOD; GLUCOSE TOLERANCE TEST; GLYCEMIC INDEX; HEART INFARCTION; HUMAN; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; LIPOTOXICITY; LOW CALORY DIET; LOW FAT DIET; METABOLIC SYNDROME X; OBESITY;

ANIMALS; DIET; FATTY ACIDS; FOOD HABITS; HUMANS; INSULIN RESISTANCE; METABOLIC SYNDROME X; OBESITY; WEIGHT LOSS;

EID: 84893509291     PISSN: 15701611     EISSN: 18756212     Source Type: Journal    
DOI: 10.2174/15701611113116660173     Document Type: Article

References (179)

1. Isomaa B, Almgren P, Tuomi T, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes care 2001; 24(4): 683-9.
2. Lorenzo C, Okoloise M, Williams K, Stern MP, Haffner SM. The metabolic syndrome as predictor of type 2 diabetes: the San Antonio heart study. Diabetes care 2003; 26(11): 3153-9.
3. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001; 285(19): 2486-97.
4. Alberti KG, Zimmet P, Shaw J. The metabolic syndrome-a new worldwide definition. Lancet 2005; 366(9491): 1059-62.
5. Kahn R, Buse J, Ferrannini E, Stern M. The metabolic syndrome: time for a critical appraisal. Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2005; 48(9): 1684-99.
6. Simmons RK, Alberti KG, Gale EA, et al. The metabolic syndrome: useful concept or clinical tool? Report of a WHO Expert Consultation. Diabetologia 2010; 53(4): 600-5.
7. Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics--2011 update: a report from the American Heart Association. Circulation 2011; 123(4): e18-e209.
8. Smith SC, Jr. Reducing the global burden of ischemic heart disease and stroke: a challenge for the cardiovascular community and the United Nations. Circulation 2011; 124(3): 278-9.
9. Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009; 120(16): 1640-5.
10. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabetic medicine: a journal of the British Diabetic Association 1998; 15(7): 539-53.
11. Kahn SE, Prigeon RL, Schwartz RS, et al. Obesity, body fat distribution, insulin sensitivity and Islet beta-cell function as explanations for metabolic diversity. J Nutr 2001; 131(2): 354S-60S.
12. Despres JP, Lemieux I. Abdominal obesity and metabolic syndrome. Nature 2006; 444(7121): 881-7.
13. Karpe F, Dickmann JR, Frayn KN. Fatty acids, obesity, and insulin resistance: time for a reevaluation. Diabetes 2011; 60(10): 2441-9.
14. Hotamisligil GS. Inflammation and metabolic disorders. Nature 2006; 444(7121): 860-7.
15. Hotta K, Funahashi T, Arita Y, et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arteriosclerosis Thrombosis Vasc Biol 2000; 20(6): 1595-9.
16. Peter P, Nuttall SL, Kendall MJ. Insulin resistance-the new goal! J Clin Pharm Ther 2003; 28(3): 167-74.
17. Poitout V, Robertson RP. An integrated view of beta-cell dysfunction in type-II diabetes. Annu Rev Med 1996; 47: 69-83.
18. Tamemoto H, Kadowaki T, Tobe K, et al. Insulin resistance and growth retardation in mice lacking insulin receptor substrate-1. Nature 1994; 372(6502): 182-6.
19. Goldstein BJ. Insulin resistance: from benign to type 2 diabetes mellitus. Rev Cardiovasc Med 2003; 4 Suppl 6: S3-10.
20. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988; 37(12): 1595-607.
21. Charles MA, Eschwege E, Thibult N, et al. The role of nonesterified fatty acids in the deterioration of glucose tolerance in Caucasian subjects: results of the Paris Prospective Study. Diabetologia 1997; 40(9): 1101-6.
22. Tripathy D, Mohanty P, Dhindsa S, et al. Elevation of free fatty acids induces inflammation and impairs vascular reactivity in healthy subjects. Diabetes 2003; 52(12): 2882-7.
23. Empana JP, Ducimetiere P, Charles MA, Jouven X. Sagittal abdominal diameter and risk of sudden death in asymptomatic middle-aged men: the Paris Prospective Study I. Circulation 2004; 110(18): 2781-5.
24. U. K. Prospective Diabetes Study 27. Plasma lipids and lipoproteins at diagnosis of NIDDM by age and sex. Diabetes Care 1997; 20(11): 1683-7.
25. Ryden L, Standl E, Bartnik M, et al. Guidelines on diabetes, prediabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 2007; 28(1): 88-136.
26. Chan DC, Barrett HP, Watts GF. Dyslipidemia in visceral obesity: mechanisms, implications, and therapy. Am J Cardiovasc Drugs 2004; 4(4): 227-46.
27. Couillard C, Bergeron N, Prud'homme D, et al. Postprandial triglyceride response in visceral obesity in men. Diabetes 1998; 47(6): 953-60.
28. Franceschini G. Epidemiologic evidence for high-density lipoprotein cholesterol as a risk factor for coronary artery disease. Am J Cardiol 2001; 88(12A): 9N-13N.
29. Pascot A, Lemieux I, Prud'homme D, et al. Reduced HDL particle size as an additional feature of the atherogenic dyslipidemia of abdominal obesity. J Lipid Res 2001; 42(12): 2007-14.
30. Lindley VA. A new procedure for handling impervious biological specimens. Microsc Res Tech 1992; 21(4): 355-60.
31. Lloyd-Jones DM, Hong Y, et al. Defining and setting national goals for cardiovascular health promotion and disease reduction: the American Heart Association's strategic Impact Goal through 2020 and beyond. Circulation 2010; 121(4): 586-61.
32. Lloyd-Jones DM, Leip EP, Larson MG, et al. Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age. Circulation 2006; 113(6): 791-8.
33. Kullo IJ, Cooper LT. Early identification of cardiovascular risk using genomics and proteomics. Nat Rev Cardiol 2010; 7(6): 309-17.
34. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005; 112(17): 2735-52.
35. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New Engl J Med 2002; 346(6): 393-403.
36. Wolongevicz DM, Zhu L, Pencina MJ, et al. Diet quality and obesity in women: the Framingham Nutrition Studies. Brit J Nutr 2010; 103(8): 1223-9.
37. Iqbal R, Anand S, Ounpuu S, et al. Dietary patterns and the risk of acute myocardial infarction in 52 countries: results of the INTERHEART study. Circulation 2008; 118(19): 1929-37.
38. Mente A, Yusuf S, Islam S, et al. Metabolic syndrome and risk of acute myocardial infarction a case-control study of 26, 903 subjects from 52 countries. J Am Coll Cardiol 2010; 55(21): 2390-8.
39. Carnethon MR, Loria CM, Hill JO, Sidney S, Savage PJ, Liu K. Risk factors for the metabolic syndrome: the Coronary Artery Risk Development in Young Adults (CARDIA) study, 1985-2001. Diabetes Care 2004; 27(11): 2707-15.
40. Ferreira I, Twisk JW, van Mechelen W, Kemper HC, Stehouwer CD. Development of fatness, fitness, and lifestyle from adolescence to the age of 36 years: determinants of the metabolic syndrome in young adults: the amsterdam growth and health longitudinal study. Arc Int Med 2005; 165(1): 42-8.
41. Dhingra R, Sullivan L, Jacques PF, et al. Soft drink consumption and risk of developing cardiometabolic risk factors and the metabolic syndrome in middle-aged adults in the community. Circulation 2007; 116(5): 480-8.
42. Mirmiran P, Noori N, Azizi F. A prospective study of determinants of the metabolic syndrome in adults. Nutrition, metabolism, and cardiovascular diseases: NMCD 2008; 18(8): 567-73.
43. Lutsey PL, Steffen LM, Stevens J. Dietary intake and the development of the metabolic syndrome: the Atherosclerosis Risk in Communities study. Circulation 2008; 117(6): 754-61.
44. Lopez-Garcia E, Schulze MB, Meigs JB, et al. Consumption of Trans Fatty Acids Is Related to Plasma Biomarkers of Inflammation and Endothelial Dysfunction. J Nutr 2005; 135(3): 562-6.
45. Mozaffarian D, Pischon T, Hankinson SE, et al. Dietary intake of trans fatty acids and systemic inflammation in women. Am J Clin Nutr 2004; 79(4): 606-12.
46. Sun Q, Ma J, Campos H, et al. A Prospective Study of Trans Fatty Acids in Erythrocytes and Risk of Coronary Heart Disease. Circulation 2007; 115(14): 1858-65.
47. Astrup A, Dyerberg J, Elwood P, et al. The role of reducing intakes of saturated fat in the prevention of cardiovascular disease: where does the evidence stand in 2010? Am J Clin Nutr 2011; 93(4): 684-8.
48. Jakobsen MU, O'Reilly EJ, Heitmann BL, et al. Major types of dietary fat and risk of coronary heart disease: a pooled analysis of 11 cohort studies. Am J Clin Nutr 2009; 89(5): 1425-32.
49. Clarke R, Shipley M, Armitage J, Collins R, Harris W. Plasma phospholipid fatty acids and CHD in older men: Whitehall study of London civil servants. Brit J Nutr 2009; 102(2): 279-84.
50. Jakobsen MU, Dethlefsen C, Joensen AM, et al. Intake of carbohydrates compared with intake of saturated fatty acids and risk of myocardial infarction: importance of the glycemic index. Am J Clin Nutr 2010; 91(6): 1764-8.
51. Mozaffarian D, Rimm EB. Fish intake, contaminants, and human health: evaluating the risks and the benefits. JAMA 2006; 296(15): 1885-99.
52. Tierney AC, McMonagle J, Shaw DI, et al. Effects of dietary fat modification on insulin sensitivity and on other risk factors of the metabolic syndrome-LIPGENE: a European randomized dietary intervention study. Int J Obes (Lond) 2011; 35(6): 800-9.
53. Meyer BJ, Lane AE, Mann NJ. Comparison of seal oil to tuna oil on plasma lipid levels and blood pressure in hypertriglyceridaemic subjects. Lipids 2009; 44(9): 827-35.
54. Julius U. Fat modification in the diabetes diet. Exp Clin Endocrinol Diabetes 2003; 111(2): 60-5.
55. Cicero AF, Ertek S, Borghi C. Omega-3 polyunsaturated fatty acids: their potential role in blood pressure prevention and management. Curr Vasc Pharmacol 2009; 7(3): 330-7.
56. Borghi C, Cicero AF. Omega-3 polyunsaturated fatty acids: Their potential role in blood pressure prevention and management. Heart Int 2006; 2(2): 98.
57. Lopez-Garcia E, Schulze MB, Manson JE, et al. Consumption of (n-3) Fatty Acids Is Related to Plasma Biomarkers of Inflammation and Endothelial Activation in Women. J Nutr 2004; 134(7): 1806-11.
58. Dangardt F, Osika W, Chen Y, et al. Omega-3 fatty acid supplementation improves vascular function and reduces inflammation in obese adolescents. Atherosclerosis 2010; 212(2): 580-5.
59. McEwen B, Morel-Kopp MC, Tofler G, Ward C. Effect of omega-3 fish oil on cardiovascular risk in diabetes. Diabetes Educator 2010; 36(4): 565-84.
60. Kaushik M, Mozaffarian D, Spiegelman D, Manson JE, Willett WC, Hu FB. Long-chain omega-3 fatty acids, fish intake, and the risk of type 2 diabetes mellitus. Am J Clin Nutr 2009; 90(3): 613-20.
61. Due A, Larsen TM, Hermansen K, et al. Comparison of the effects on insulin resistance and glucose tolerance of 6-mo highmonounsaturated-fat, low-fat, and control diets. Am J Clin Nutr 2008; 87(4): 855-62.
62. Sloth B, Due A, Larsen TM, Holst JJ, Heding A, Astrup A. The effect of a high-MUFA, low-glycaemic index diet and a low-fat diet on appetite and glucose metabolism during a 6-month weight maintenance period. Brit J Nutr 2009; 101(12): 1846-58.
63. Due A, Larsen TM, Mu H, Hermansen K, Stender S, Astrup A. Comparison of 3 ad libitum diets for weight-loss maintenance, risk of cardiovascular disease, and diabetes: a 6-mo randomized, controlled trial. Am J Clin Nutr 2008; 88(5): 1232-41.
64. Rivellese AA, Maffettone A, Vessby B, et al. Effects of dietary saturated, monounsaturated and n-3 fatty acids on fasting lipoproteins, LDL size and post-prandial lipid metabolism in healthy subjects. Atherosclerosis 2003; 167(1): 149-58.
65. Thomsen C, Rasmussen O, Lousen T, et al. Differential effects of saturated and monounsaturated fatty acids on postprandial lipemia and incretin responses in healthy subjects. Am J Clin Nutr 1999; 69(6): 1135-43.
66. Rasmussen BM, Vessby B, Uusitupa M, et al. Effects of dietary saturated, monounsaturated, and n-3 fatty acids on blood pressure in healthy subjects. Am J Clin Nutr. 2006; 83(2): 221-6.
67. Vessby B, Uusitupa M, Hermansen K, et al. Substituting dietary saturated for monounsaturated fat impairs insulin sensitivity in healthy men and women: The KANWU Study. Diabetologia 2001; 44(3): 312-9.
68. Paniagua JA, Gallego de la Sacristana A, Romero I, et al. Monounsaturated fat-rich diet prevents central body fat distribution and decreases postprandial adiponectin expression induced by a carbohydrate-rich diet in insulin-resistant subjects. Diabetes Care 2007; 30(7): 1717-23.
69. Pajvani UB, Scherer PE. Adiponectin: systemic contributor to insulin sensitivity. Current Diabetes Rep 2003; 3(3): 207-13.
70. Walker KZ, O'Dea K, Johnson L, et al. Body fat distribution and non-insulin-dependent diabetes: comparison of a fiber-rich, highcarbohydrate, low-fat (23%) diet and a 35% fat diet high in monounsaturated fat. Am J Clin Nutr 1996; 63(2): 254-60.
71. Key TJ, Fraser GE, Thorogood M, et al. Mortality in vegetarians and non-vegetarians: a collaborative analysis of 8300 deaths among 76, 000 men and women in five prospective studies. Public Health Nutr 1998; 1(1): 33-41.
72. Perez-Jimenez F, Lopez-Miranda J, Pinillos MD, et al. A Mediterranean and a high-carbohydrate diet improve glucose metabolism in healthy young persons. Diabetologia 2001; 44(11): 2038-43.
73. Paniagua JA, de la Sacristana AG, Sanchez E, et al. A MUFA-rich diet improves posprandial glucose, lipid and GLP-1 responses in insulin-resistant subjects. J Am Coll Nutr 2007; 26(5): 434-44.
74. Field AE, Willett WC, Lissner L, Colditz GA. Dietary fat and weight gain among women in the Nurses' Health Study. Obesity (Silver Spring). 2007; 15(4): 967-76.
75. He K, Merchant A, Rimm EB, et al. Dietary fat intake and risk of stroke in male US healthcare professionals: 14 year prospective cohort study. BMJ. 2003; 327(7418): 777-82.
76. Hu FB, Stampfer MJ, Manson JE, et al. Dietary fat intake and the risk of coronary heart disease in women. New Engl J Med 1997; 337(21): 1491-9.
77. Koh-Banerjee P, Chu NF, Spiegelman D, et al. Prospective study of the association of changes in dietary intake, physical activity, alcohol consumption, and smoking with 9-y gain in waist circumference among 16 587 US men. Am J Clin Nutr. 2003; 78(4): 719-27.
78. Xu J, Eilat-Adar S, Loria C, et al. Dietary fat intake and risk of coronary heart disease: the Strong Heart Study. Am J Clin Nutr 2006; 84(4): 894-902.
79. Astrup A. The role of dietary fat in the prevention and treatment of obesity. Efficacy and safety of low-fat diets. Int J Obes Relat Metab Disord 2001; 25 Suppl 1: S46-50.
80. Jequier E. Response to and range of acceptable fat intake in adults. Eur J Clin Nutr 1999; 53 Suppl 1: S84-8; discussion S8-93.
81. Fats and fatty acids in human nutrition. Proceedings of the Joint FAO/WHO Expert Consultation. November 10-14, 2008. Geneva, Switzerland. Ann Nutr Metab 2009; 55(1-3): 5-300.
82. Jenkins D, Wolever T, Taylor R, et al. Glycemic index of foods: a physiological basis for carbohydrate exchange. The American J Clin Nutr 1981; 34(3): 362-6.
83. Brand-Miller JC, Holt SH, Pawlak DB, McMillan J. Glycemic index and obesity. Am J Clin Nutr 2002; 76(1): 281S-5S.
84. Borneo R, Leon AE. Whole grain cereals: functional components and health benefits. Food Funct 2011.
85. Schulze MB, Liu S, Rimm EB, Manson JE, Willett WC, Hu FB. Glycemic index, glycemic load, and dietary fiber intake and incidence of type 2 diabetes in younger and middle-aged women. Am J Clin Nutr 2004; 80(2): 348-56.
86. Salmeron J, Ascherio A, Rimm EB, et al. Dietary fiber, glycemic load, and risk of NIDDM in men. Diabetes Care 1997; 20(4): 545-50.
87. Sluijs I, van der Schouw YT, van der AD, et al. Carbohydrate quantity and quality and risk of type 2 diabetes in the European Prospective Investigation into Cancer and Nutrition-Netherlands (EPIC-NL) study. Am J Clin Nutr 2010; 92(4): 905-11.
88. Oh K, Hu FB, Manson JE, Stampfer MJ, Willett WC. Dietary Fat Intake and Risk of Coronary Heart Disease in Women: 20 Years of Follow-up of the Nurses' Health Study. Am J Epidemiol 2005; 161(7): 672-9.
89. Barclay AW, Petocz P, McMillan-Price J, et al. Glycemic index, glycemic load, and chronic disease risk-a meta-analysis of observational studies. Am J Clin Nutr 2008; 87(3): 627-37.
90. Wu T, Giovannucci E, Pischon T, et al. Fructose, glycemic load, and quantity and quality of carbohydrate in relation to plasma Cpeptide concentrations in US women. Am J Clin Nutr 2004; 80(4): 1043-9.
91. Liu S, Manson JE, Buring JE, Stampfer MJ, Willett WC, Ridker PM. Relation between a diet with a high glycemic load and plasma concentrations of high-sensitivity C-reactive protein in middle-aged women. Am J Clin Nutr 2002; 75(3): 492-8.
92. Sloth B, Krog-Mikkelsen I, Flint A, et al. No difference in body weight decrease between a low-glycemic-index and a highglycemic-index diet but reduced LDL cholesterol after 10-wk ad libitum intake of the low-glycemic-index diet. Am J Clin Nutr 2004; 80(2): 337-47.
93. Shikany JM, Phadke RP, Redden DT, Gower BA. Effects of lowand high-glycemic index/glycemic load diets on coronary heart disease risk factors in overweight/obese men. Metab: Clin Exp 2009; 58(12): 1793-801.
94. Jarvi AE, Karlstrom BE, Granfeldt YE, Bjorck IE, Asp NG, Vessby BO. Improved glycemic control and lipid profile and normalized fibrinolytic activity on a low-glycemic index diet in type 2 diabetic patients. Diabetes Care 1999; 22(1): 10-8.
95. Heilbronn LK, Noakes M, Clifton PM. The effect of high-and lowglycemic index energy restricted diets on plasma lipid and glucose profiles in type 2 diabetic subjects with varying glycemic control. J Am Coll Nutr 2002; 21(2): 120-7.
96. Larsen TM, Dalskov SM, van Baak M, et al. Diets with high or low protein content and glycemic index for weight-loss maintenance. New Engl J Med 2010; 363(22): 2102-13.
97. Gogebakan O, Kohl A, Osterhoff MA, et al. Effects of Weight Loss and Long-Term Weight Maintenance With Diets Varying in Protein and Glycemic Index on Cardiovascular Risk Factors: The Diet, Obesity, and Genes (DiOGenes) Study: A Randomized, Controlled Trial. Circulation 2011; 124(25): 2829-38.
98. Wolever TM, Gibbs AL, Mehling C, et al. The Canadian Trial of Carbohydrates in Diabetes (CCD), a 1-y controlled trial of lowglycemic-index dietary carbohydrate in type 2 diabetes: no effect on glycated hemoglobin but reduction in C-reactive protein. Am J Clin Nutr 2008; 87(1): 114-25.
99. Du H, van der AD, van Bakel MM, et al. Glycemic index and glycemic load in relation to food and nutrient intake and metabolic risk factors in a Dutch population. Am J Clin Nutr 2008; 87(3): 655-61.
100. Liu S, Manson JE, Stampfer MJ, et al. Dietary glycemic load assessed by food-frequency questionnaire in relation to plasma high-density-lipoprotein cholesterol and fasting plasma triacylglycerols in postmenopausal women. Am J Clin Nutr 2001; 73(3): 560-6.
101. van Dam RM, Visscher AW, Feskens EJ, Verhoef P, Kromhout D. Dietary glycemic index in relation to metabolic risk factors and incidence of coronary heart disease: the Zutphen Elderly Study. Eur J Clin Nutr 2000; 54(9): 726-31.
102. Oxlund AL, Heitmann BL. Glycaemic index and glycaemic load in relation to blood lipids-6 years of follow-up in adult Danish men and women. Public Health Nutr 2006; 9(6): 737-45.
103. Sacks FM, Obarzanek E, Windhauser MM, et al. Rationale and design of the Dietary Approaches to Stop Hypertension trial (DASH): A multicenter controlled-feeding study of dietary patterns to lower blood pressure. Ann Epidemiol 1995; 5(2): 108-18.
104. Appel LJ, Moore TJ, Obarzanek E, Vollmer WM, Svetkey LP, Sacks FM, et al. A Clinical Trial of the Effects of Dietary Patterns on Blood Pressure. New Engl J Med 1997; 336(16): 1117-24.
105. Svetkey LP, Simons-Morton D, Vollmer WM, et al. Effects of Dietary Patterns on Blood Pressure: Subgroup Analysis of the Dietary Approaches to Stop Hypertension (DASH) Randomized Clinical Trial. Arch Intern Med 1999; 159(3): 285-93.
106. Prather AA, Blumenthal JA, Hinderliter AL, Sherwood A. Ethnic Differences in the Effects of the DASH Diet on Nocturnal Blood Pressure Dipping in Individuals with High Blood Pressure. Am J Hypertens 2011; 24(12): 1338-44.
107. Obarzanek E, Sacks FM, Vollmer WM, et al. Effects on blood lipids of a blood pressureÂ-lowering diet: the Dietary Approaches to Stop Hypertension (DASH) Trial. Am J Clin Nutr. 2001; 74(1): 80-9.
108. Azadbakht L, Fard NRP, Karimi M, et al. Effects of the Dietary Approaches to Stop Hypertension (DASH) Eating Plan on Cardiovascular Risks Among Type 2 Diabetic Patients. Diabetes Care 2011; 34(1): 55-7.
109. Azadbakht L, Surkan PJ, Esmaillzadeh A, Willett WC. The Dietary Approaches to Stop Hypertension Eating Plan Affects C-Reactive Protein, Coagulation Abnormalities, and Hepatic Function Tests among Type 2 Diabetic Patients. J Nutr 2011; 141(6): 1083-8.
110. Liese AD, Nichols M, Sun X, D'Agostino RB, Haffner SM. Adherence to the DASH Diet Is Inversely Associated With Incidence of Type 2 Diabetes: The Insulin Resistance Atherosclerosis Study. Diabetes Care 2009; 32(8): 1434-6.
111. Azadbakht L, Mirmiran P, Esmaillzadeh A, Azizi T, Azizi F. Beneficial Effects of a Dietary Approaches to Stop Hypertension Eating Plan on Features of the Metabolic Syndrome. Diabetes Care 2005; 28(12): 2823-31.
112. Kimokoti RW, Brown LS. Dietary management of the metabolic syndrome. Clin Pharmacol Ther 2011; 90(1): 184-7.
113. Pan XR, Li GW, Hu YH, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care 1997; 20(4): 537-44.
114. Paniagua JA, Perez-Martinez P, Gjelstad IM, et al. A low-fat highcarbohydrate diet supplemented with long-chain n-3 PUFA reduces the risk of the metabolic syndrome. Atherosclerosis 2011; 218(2): 443-50.
115. Roumen C, Corpeleijn E, Feskens EJ, Mensink M, Saris WH, Blaak EE. Impact of 3-year lifestyle intervention on postprandial glucose metabolism: the SLIM study. Diabet Med 2008; 25(5): 597-605.
116. Lindstrom J, Louheranta A, Mannelin M, et al. The Finnish Diabetes Prevention Study (DPS): Lifestyle intervention and 3-year results on diet and physical activity. Diabetes Care 2003; 26(12): 3230-6.
117. Tuomilehto J, Lindstrom J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. New Engl J Med 2001; 344(18): 1343-50.
118. Ilanne-Parikka P, Eriksson JG, Lindstrom J, et al. Effect of lifestyle intervention on the occurrence of metabolic syndrome and its components in the Finnish Diabetes Prevention Study. Diabetes Care 2008; 31(4): 805-7.
119. Lindstrom J, Ilanne-Parikka P, Peltonen M, et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet 2006; 368(9548): 1673-9.
120. Lindstrom J, Peltonen M, Eriksson JG, et al. High-fibre, low-fat diet predicts long-term weight loss and decreased type 2 diabetes risk: the Finnish Diabetes Prevention Study. Diabetologia 2006; 49(5): 912-20.
121. The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care 2002; 25(12): 2165-71.
122. Hamman RF, Wing RR, Edelstein SL, et al. Effect of weight loss with lifestyle intervention on risk of diabetes. Diabetes Care 2006; 29(9): 2102-7.
123. Kitabchi AE, Temprosa M, Knowler WC, et al. Role of insulin secretion and sensitivity in the evolution of type 2 diabetes in the diabetes prevention program: effects of lifestyle intervention and metformin. Diabetes 2005; 54(8): 2404-14.
124. Mather KJ, Funahashi T, Matsuzawa Y, et al. Adiponectin, change in adiponectin, and progression to diabetes in the Diabetes Prevention Program. Diabetes 2008; 57(4): 980-6.
125. Festa A, D'Agostino R, Jr., Tracy RP, Haffner SM. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes 2002; 51(4): 1131-7.
126. Devaraj S, Valleggi S, Siegel D, Jialal I. Role of C-reactive protein in contributing to increased cardiovascular risk in metabolic syndrome. Curr Atherosclerosis Rep 2010; 12(2): 110-8.
127. Haffner S, Temprosa M, Crandall J, et al. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes 2005; 54(5): 1566-72.
128. Ratner RE. An update on the Diabetes Prevention Program. Endocrine practice: official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists. 2006; 12 Suppl 1: 20-4.
129. Ratner R, Goldberg R, Haffner S, et al. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the diabetes prevention program. Diabetes Care 2005; 28(4): 888-94.
130. Knowler WC, Fowler SE, Hamman RF, et al. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet 2009; 374(9702): 1677-86.
131. Mensink M, Feskens EJ, Saris WH, De Bruin TW, Blaak EE. Study on Lifestyle Intervention and Impaired Glucose Tolerance Maastricht (SLIM): preliminary results after one year. Int J Obes Relat Metab Disord. 2003; 27(3): 377-84.
132. Corpeleijn E, Feskens EJ, Jansen EH, et al. Improvements in glucose tolerance and insulin sensitivity after lifestyle intervention are related to changes in serum fatty acid profile and desaturase activities: the SLIM study. Diabetologia 2006; 49(10): 2392-401.
133. Hardy G. Nutraceuticals and functional foods: introduction and meaning. Nutrition 2000; 16(7-8): 688-9.
134. Kwak NS, Jukes DJ. Current international approaches to food claims. Nutr Rev 2000; 58(12): 370-7.
135. Stanton C, Ross RP, Fitzgerald GF, Van Sinderen D. Fermented functional foods based on probiotics and their biogenic metabolites. Curr Opin Biotechnol 2005; 16(2): 198-203.
136. Lordan S, Ross RP, Stanton C. Marine bioactives as functional food ingredients: potential to reduce the incidence of chronic diseases. Marine Drugs 2011; 9(6): 1056-100.
137. Kitts DD. Bioactive substances in food: identification and potential uses. Can J Physiol Pharmacol 1994; 72(4): 423-34.
138. Marinangeli CP, Jones PJ. Functional food ingredients as adjunctive therapies to pharmacotherapy for treating disorders of metabolic syndrome. Ann Med 2010; 42(5): 317-33.
139. Cherniack EP. Polyphenols: planting the seeds of treatment for the metabolic syndrome. Nutrition 2011; 27(6): 617-23.
140. Siro I, Kapolna E, Kapolna B, Lugasi A. Functional food. Product development, marketing and consumer acceptance-a review. Appetite 2008; 51(3): 456-67.
141. Oliver E, McGillicuddy FC, Harford KA, et al. Docosahexaenoic acid attenuates macrophage-induced inflammation and improves insulin sensitivity in adipocytes-specific differential effects between LC n-3 PUFA. J Nutr Biochem 2011. Epub 2011/12/06.
142. El Khoury D, Cuda C, Luhovyy BL, Anderson GH. Beta glucan: health benefits in obesity and metabolic syndrome. J Nutr Metab 2012; 2012: 851362.
143. Cam A, de Mejia EG. Role of dietary proteins and peptides in cardiovascular disease. Mol Nutr Food Res 2012; 56(1): 53-66.
144. Sano J, Ohki K, Higuchi T, et al. Effect of casein hydrolysate, prepared with protease derived from Aspergillus oryzae, on subjects with high-normal blood pressure or mild hypertension. J Med Food 2005; 8(4): 423-30.
145. Mizuno S, Matsuura K, Gotou T, et al. Antihypertensive effect of casein hydrolysate in a placebo-controlled study in subjects with high-normal blood pressure and mild hypertension. Br J Nutr 2005; 94(1): 84-91.
146. Puddu P, Latorre D, Carollo M, et al. Bovine lactoferrin counteracts Toll-like receptor mediated activation signals in antigen presenting cells. PLoS One 2011; 6(7): e22504.
147. Bharadwaj S, Naidu TA, Betageri GV, Prasadarao NV, Naidu AS. Inflammatory responses improve with milk ribonuclease-enriched lactoferrin supplementation in postmenopausal women. Inflamm Res 2010; 59(11): 971-8.
148. Ono T, Murakoshi M, Suzuki N, et al. Potent anti-obesity effect of enteric-coated lactoferrin: decrease in visceral fat accumulation in Japanese men and women with abdominal obesity after 8-week administration of enteric-coated lactoferrin tablets. Br J Nutr 2010; 104(11): 1688-95.
149. Keogh JB, Clifton P. The effect of meal replacements high in glycomacropeptide on weight loss and markers of cardiovascular disease risk. Am J Clin Nutr 2008; 87(6): 1602-5.
150. Pupovac J, Anderson GH. Dietary peptides induce satiety via cholecystokinin-A and peripheral opioid receptors in rats. J Nutr 2002; 132(9): 2775-80.
151. Froetschel MA, Azain MJ, Edwards GL, Barb CR, Amos HE. Opioid and cholecystokinin antagonists alleviate gastric inhibition of food intake by premeal loads of casein in meal-fed rats. J Nutr 2001; 131(12): 3270-6.
152. Shimizu M, Sawashita N, Morimatsu F, et al. Antithrombotic papain-hydrolyzed peptides isolated from pork meat. Thrombosis Res 2009; 123(5): 753-7.
153. Zhang Y, Kouguchi T, Shimizu K, Sato M, Takahata Y, Morimatsu F. Chicken collagen hydrolysate reduces proinflammatory cytokine production in C57BL/6. KOR-ApoEshl mice. J Nutr Sci Vitaminol 2010; 56(3): 208-10.
154. Zhang Y, Kouguchi T, Shimizu M, Ohmori T, Takahata Y, Morimatsu F. Chicken collagen hydrolysate protects rats from hypertension and cardiovascular damage. J Med Food 2010; 13(2): 399-405.
155. Qin B, Nagasaki M, Ren M, Bajotto G, Oshida Y, Sato Y. Cinnamon extract (traditional herb) potentiates in vivo insulinregulated glucose utilization via enhancing insulin signaling in rats. Diabetes Res Clin Pract 2003; 62(3): 139-48.
156. Imparl-Radosevich J, Deas S, Polansky MM, et al. Regulation of PTP-1 and insulin receptor kinase by fractions from cinnamon: implications for cinnamon regulation of insulin signalling. Hormone Res 1998; 50(3): 177-82.
157. Waltner-Law ME, Wang XL, Law BK, Hall RK, Nawano M, Granner DK. Epigallocatechin gallate, a constituent of green tea, represses hepatic glucose production. J Biol Chem 2002; 277(38): 34933-40.
158. Zhou L, Yang Y, Wang X, et al. Berberine stimulates glucose transport through a mechanism distinct from insulin. Metab Clin Exp 2007; 56(3): 405-12.
159. Lai DM, Tu YK, Liu IM, Chen PF, Cheng JT. Mediation of betaendorphin by ginsenoside Rh2 to lower plasma glucose in streptozotocin-induced diabetic rats. Planta Med 2006; 72(1): 9-13.
160. Zhang Z, Li X, Lv W, et al. Ginsenoside Re reduces insulin resistance through inhibition of c-Jun NH2-terminal kinase and nuclear factor-kappaB. Mol Endocrinol 2008; 22(1): 186-95.
161. Roussel AM, Hininger I, Benaraba R, Ziegenfuss TN, Anderson RA. Antioxidant effects of a cinnamon extract in people with impaired fasting glucose that are overweight or obese. J Am Coll Nutr 2009; 28(1): 16-21.
162. Ziegenfuss TN, Hofheins JE, Mendel RW, Landis J, Anderson RA. Effects of a water-soluble cinnamon extract on body composition and features of the metabolic syndrome in pre-diabetic men and women. J Int Soc Sports Nutr 2006; 3: 45-53.
163. Bose M, Lambert JD, Ju J, Reuhl KR, Shapses SA, Yang CS. The major green tea polyphenol, (-)-epigallocatechin-3-gallate, inhibits obesity, metabolic syndrome, and fatty liver disease in high-fat-fed mice. J Nutr 2008; 138(9): 1677-83.
164. Potenza MA, Marasciulo FL, Tarquinio M, et al. EGCG, a green tea polyphenol, improves endothelial function and insulin sensitivity, reduces blood pressure, and protects against myocardial I/R injury in SHR. Am J Physiol Endocrinol Metab 2007; 292(5): E1378-87.
165. Wolfram S. Effects of green tea and EGCG on cardiovascular and metabolic health. J Am Coll Nutr 2007; 26(4): 373S-88S.
166. Hill AM, Coates AM, Buckley JD, Ross R, Thielecke F, Howe PR. Can EGCG reduce abdominal fat in obese subjects? J Am Coll Nutr 2007; 26(4): 396S-402S.
167. Zhang Y, Li X, Zou D, et al. Treatment of type 2 diabetes and dyslipidemia with the natural plant alkaloid berberine. J Clin Endocrinol Metab 2008; 93(7): 2559-65.
168. Yin J, Xing H, Ye J. Efficacy of berberine in patients with type 2 diabetes mellitus. Metab Clin Exp 2008; 57(5): 712-7.
169. Strobel P, Allard C, Perez-Acle T, Calderon R, Aldunate R, Leighton F. Myricetin, quercetin and catechin-gallate inhibit glucose uptake in isolated rat adipocytes. Biochem J 2005; 386(Pt 3): 471-8.
170. Wang A, Liu M, Liu X, et al. Up-regulation of adiponectin by resveratrol: the essential roles of the Akt/FOXO1 and AMPactivated protein kinase signaling pathways and DsbA-L. J Biol Chem 2011; 286(1): 60-6.
171. Rivera L, Moron R, Sanchez M, Zarzuelo A, Galisteo M. Quercetin ameliorates metabolic syndrome and improves the inflammatory status in obese Zucker rats. Obesity (Silver Spring). 2008; 16(9): 2081-7.
172. Egert S, Bosy-Westphal A, Seiberl J, et al. Quercetin reduces systolic blood pressure and plasma oxidised low-density lipoprotein concentrations in overweight subjects with a highcardiovascular disease risk phenotype: a double-blinded, placebocontrolled cross-over study. Br J Nutr 2009; 102(7): 1065-74.
173. Timmers S, Konings E, Bilet L, Houtkooper R, et al. Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell Metab 2011; 14(5): 612-22.
174. Bertelli AA, Das DK. Grapes, wines, resveratrol, and heart health. J Cardiovasc Pharmacol 2009; 54(6): 468-76.
175. Opie LH, Lecour S. The red wine hypothesis: from concepts to protective signalling molecules. Eur Heart J 2007; 28(14): 1683-93.
176. Magyar K, Halmosi R, Palfi A, et al. Cardioprotection by resveratrol: A human clinical trial in patients with stable coronary artery disease. Clin Hemorheol Microcirc 2012 50(3): 179-87.
177. Brasnyo P, Molnar GA, Mohas M, et al. Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients. Brit J Nutr 2011; 106(3): 383-9.
178. Goldberg DM, Yan J, Soleas GJ. Absorption of three wine-related polyphenols in three different matrices by healthy subjects. Clin Biochem. 2003; 36(1): 79-87.
179. AbuMweis SS, Jew S, Jones PJ. Optimizing clinical trial design for assessing the efficacy of functional foods. Nutr Rev 2010; 68(8): 485-99.